Viking Therapeutics, Inc. (ETR:1VT)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.39B +36.7% |
| Revenue (ttm) | n/a |
| Net Income | -468.11M |
| EPS | -4.09 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 29.20 |
| Previous Close | 29.45 |
| Day's Range | 29.20 - 29.20 |
| 52-Week Range | 24.65 - 36.45 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c... [Read more]
News
Viking Therapeutics price target lowered to $65 from $75 at JPMorgan
JPMorgan analyst Hardik Parikh lowered the firm’s price target on Viking Therapeutics (VKTX) to $65 from $75 and keeps an Overweight rating on the shares.
3 Best Stocks With 100%+ Upside to Buy This Week, According to Analysts
Analysts see strong momentum in some stocks this week, including Viking Therapeutics ($VKTX), USA Rare Earth ($USAR), and NextNav ($NN). While each stock carries risk, analysts believe all three have ...
Viking Therapeutics participates in a conference call with Cantor
Conference call with management to be held on August 13 at 11 am hosted by Cantor.
Viking Therapeutics Slides: Corporate presentation
Viking Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Viking Therapeutics price target raised to $114 from $107 at Canaccord
Canaccord raised the firm’s price target on Viking Therapeutics (VKTX) to $114 from $107 and keeps a Buy rating on the shares. The firm said the company beat on the…
Viking Therapeutics files automatic mixed securities shelf
06:13 EDT Viking Therapeutics (VKTX) files automatic mixed securities shelf
Viking Therapeutics Earnings Call Transcript: Q2 2026
Lead obesity programs advanced with phase III trials fully enrolled and oral studies set to begin in Q4 2026. R&D expenses and net loss rose sharply year-over-year, but cash reserves remain strong, supporting operations into 2028. Key clinical and organizational milestones achieved.
Viking Therapeutics Earnings release: Q2 2026
Viking Therapeutics released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Viking Therapeutics Quarterly report: Q2 2026
Viking Therapeutics has published its Q2 2026 quarterly earnings report on July 29, 2026.
Viking Therapeutics reports Q2 EPS ($1.10) vs. (58c) last year
At June 30, Viking held cash, cash equivalents and short-term investments of $502M vs. $706M as of December 31, 2025. “During Q2, we continued to advance each program in our…
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing -- -- Oral Phase 3 VK2735 Trial Initiation Expected 4Q...
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
Experienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and Commercialization SAN DIEGO,, July 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ...
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
Conference Call Scheduled for Wednesday, July 29, at 4:30 p.m. Eastern Time SAN DIEGO, July 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceu...
Viking Therapeutics Slides: Corporate presentation
Viking Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Viking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing Strength
Viking Therapeutics continues to strengthen within a long-term bottoming pattern, but a pullback or decisive breakout above major resistance will likely determine the next trend.
Viking catalysts include VK3019, VK2735 readouts in Q3, says Raymond James
Raymond James tells investors in a research note that Viking Therapeutics (VKTX) initiated a Phase 1 single ascending dose study of VK3019, a dual amylin and calcitonin receptor agonist for…
Viking Therapeutics begins Phase 1 SAD clinical trial of VK3019
Viking Therapeutics (VKTX) announced the initiation of a Phase 1 single ascending dose, or SAD, clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist, or DACRA. VK30...
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/...
Viking Therapeutics management to meet with B. Riley
Meeting to be held in Denver on June 22 hosted by B. Riley.
Viking Therapeutics names Hubert Chen, M.D., as Chief Medical Officer
Viking Therapeutics (VKTX) announced the appointment of Hubert Chen, M.D., as chief medical officer. Dr. Chen brings more than two decades of leadership experience in senior executive roles spanning d...
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D.
Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (V...
Viking Therapeutics Slides: Corporate presentation
Viking Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 7, 2026.
Viking Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Phase III obesity trials are fully enrolled, with data expected in 2027, and an oral formulation is advancing to phase III later this year. Maintenance dosing and a novel amylin agonist are in development, while strong cash reserves support ongoing trials and commercial planning.
Viking Therapeutics initiated with a Buy at Lake Street
Lake Street initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $89 price target based on the market opportunity for the company’s lead clinical asset, VK2735 in obesity.
Viking Therapeutics assumed with a Buy at Truist
Truist assumed coverage of Viking Therapeutics (VKTX) with a Buy rating with a price target of $83, up from $75. The firm is positive on the stock as a differentiated…